The stock of Chiasma Inc (NASDAQ:CHMA) is a huge mover today! About 962,274 shares traded hands or 534.09% up from the average. Chiasma Inc (NASDAQ:CHMA) has declined 70.34% since March 2, 2016 and is downtrending. It has underperformed by 78.60% the S&P500.
The move comes after 5 months positive chart setup for the $84.34 million company. It was reported on Oct, 5 by Barchart.com. We have $5.70 PT which if reached, will make NASDAQ:CHMA worth $59.04 million more.
Analysts await Chiasma Inc (NASDAQ:CHMA) to report earnings on November, 10. They expect $-0.66 EPS, down 43.48% or $0.20 from last year’s $-0.46 per share. After $-0.83 actual EPS reported by Chiasma Inc for the previous quarter, Wall Street now forecasts -20.48% EPS growth.
Chiasma Inc (NASDAQ:CHMA) Ratings Coverage
Out of 3 analysts covering Chiasma (NASDAQ:CHMA), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Chiasma has been the topic of 5 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The rating was initiated by Barclays Capital on Monday, August 10 with “Overweight”. As per Monday, April 25, the company rating was downgraded by Barclays Capital. The firm has “Outperform” rating by William Blair given on Monday, August 10. William Blair downgraded the stock to “Market Perform” rating in Monday, April 18 report. The firm has “Outperform” rating given on Monday, August 10 by Cowen & Co.
According to Zacks Investment Research, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA.”
More notable recent Chiasma Inc (NASDAQ:CHMA) news were published by: Marketwatch.com which released: “Chiasma’s stock plummets 54% premarket after FDA response letter” on July 16, 2015, also Streetinsider.com with their article: “Chiasma, Inc. (CHMA) Names Mark J. Fitzpatrick as CEO” published on September 30, 2016, Prnewswire.com published: “Chiasma, Inc. Prices Initial Public Offering of Common Stock” on July 15, 2015. More interesting news about Chiasma Inc (NASDAQ:CHMA) were released by: Streetinsider.com and their article: “Chiasma, Inc. (CHMA) Announces Additional 44% Workforce Reduction” published on August 16, 2016 as well as Reuters.com‘s news article titled: “BRIEF-Chiasma Inc terminates employment of CCO Anand Varadan” with publication date: June 14, 2016.
CHMA Company Profile
Chiasma, Inc., incorporated on April 12, 2001, is a biopharmaceutical company. The Firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Firm has completed a Phase III clinical trial of its TPE platform product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.